Status:
COMPLETED
Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
HIV Infections
Anus Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
PRIMARY: In Phase I, to define a broadly tolerable dose of isotretinoin that can be used in combination with interferon alfa-2a (IFN alfa-2a). In Phase II, to determine trends in efficacy of isotretin...
Detailed Description
Patients with HIV infection have a significant risk of recurrence following local ablation of intraepithelial neoplasia; thus, anogenital epithelial may become an increasingly important cause of morbi...
Eligibility Criteria
Inclusion Criteria
Concurrent Medication:
Allowed:
- PCP prophylaxis (required for patients with CD4 count < 200 cells/mm3).
- Chemoprophylaxis for candidiasis and herpes simplex.
- Metronidazole for up to 14 days.
- Erythropoietin.
Patients must have:
- HIV seropositivity.
- NO active opportunistic infection requiring treatment with prohibited drugs.
- Phase I - Current grade 1 AIN (i.e., low grade SIL) OR treated or untreated grade 2 or 3 AIN (i.e., high grade SIL).
Phase II - Prior histologically confirmed grade 2 or 3 AIN / high grade SIL, with ablative therapy within the past 30-90 days.
- Capability of complying with study protocol.
NOTE:
- The terms condyloma, grade 1 AIN, and low grade SIL are interchangeable. Grade 2 or 3 AIN is interchangeable with high grade SIL.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Active medical problems for which the patient is undergoing evaluations or for which prohibited therapy is required.
- Other active malignancies requiring systemic therapy.
- Significant symptomatic cardiac disease.
NOTE:
- Patients with malignancies being managed with local therapy (e.g., Kaposi's sarcoma, basal cell carcinoma) may enroll at the discretion of the site investigator.
Concurrent Medication:
Excluded:
- G-CSF (filgrastim).
- Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).
- Corticosteroids.
- Biologic response modifiers.
- Cytotoxic chemotherapy.
Concurrent Treatment:
Excluded:
- Radiation therapy.
Patients with the following prior conditions are excluded:
History of ventricular arrhythmias or myocardial infarction.
Prior Medication:
Excluded within 20 days prior to study entry:
- G-CSF (filgrastim).
- Myelosuppressive antibiotics (except co-trimoxazole for PCP prophylaxis).
- Corticosteroids.
- Biologic response modifiers.
- Cytotoxic chemotherapy.
Prior Treatment:
Excluded within 20 days prior to study entry:
- Radiation therapy.
Excluded within 14 days prior to study entry:
- Transfusion.
Active substance abuse or illegal drug use (alcohol consumption is strongly discouraged).
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
July 1 1996
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT00000764
End Date
July 1 1996
Last Update
October 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Washington AIDS CRS
Seattle, Washington, United States, 98122